S&P 500   3,930.00 (-0.29%)
DOW   33,548.78 (-0.14%)
QQQ   280.83 (-0.30%)
AAPL   140.88 (-1.42%)
MSFT   244.16 (-0.39%)
META   113.93 (-0.17%)
GOOGL   95.73 (-1.29%)
AMZN   87.71 (-0.61%)
TSLA   173.23 (-3.66%)
NVDA   158.86 (-0.63%)
NIO   12.38 (-6.50%)
BABA   87.99 (-3.78%)
AMD   70.45 (+0.26%)
T   19.34 (+0.89%)
MU   53.52 (-0.30%)
CGC   3.37 (-6.65%)
F   13.29 (+0.08%)
GE   85.47 (+0.22%)
DIS   91.95 (-0.37%)
AMC   6.64 (-1.63%)
PYPL   72.61 (+0.53%)
PFE   50.38 (+1.35%)
NFLX   305.56 (+0.00%)
S&P 500   3,930.00 (-0.29%)
DOW   33,548.78 (-0.14%)
QQQ   280.83 (-0.30%)
AAPL   140.88 (-1.42%)
MSFT   244.16 (-0.39%)
META   113.93 (-0.17%)
GOOGL   95.73 (-1.29%)
AMZN   87.71 (-0.61%)
TSLA   173.23 (-3.66%)
NVDA   158.86 (-0.63%)
NIO   12.38 (-6.50%)
BABA   87.99 (-3.78%)
AMD   70.45 (+0.26%)
T   19.34 (+0.89%)
MU   53.52 (-0.30%)
CGC   3.37 (-6.65%)
F   13.29 (+0.08%)
GE   85.47 (+0.22%)
DIS   91.95 (-0.37%)
AMC   6.64 (-1.63%)
PYPL   72.61 (+0.53%)
PFE   50.38 (+1.35%)
NFLX   305.56 (+0.00%)
S&P 500   3,930.00 (-0.29%)
DOW   33,548.78 (-0.14%)
QQQ   280.83 (-0.30%)
AAPL   140.88 (-1.42%)
MSFT   244.16 (-0.39%)
META   113.93 (-0.17%)
GOOGL   95.73 (-1.29%)
AMZN   87.71 (-0.61%)
TSLA   173.23 (-3.66%)
NVDA   158.86 (-0.63%)
NIO   12.38 (-6.50%)
BABA   87.99 (-3.78%)
AMD   70.45 (+0.26%)
T   19.34 (+0.89%)
MU   53.52 (-0.30%)
CGC   3.37 (-6.65%)
F   13.29 (+0.08%)
GE   85.47 (+0.22%)
DIS   91.95 (-0.37%)
AMC   6.64 (-1.63%)
PYPL   72.61 (+0.53%)
PFE   50.38 (+1.35%)
NFLX   305.56 (+0.00%)
S&P 500   3,930.00 (-0.29%)
DOW   33,548.78 (-0.14%)
QQQ   280.83 (-0.30%)
AAPL   140.88 (-1.42%)
MSFT   244.16 (-0.39%)
META   113.93 (-0.17%)
GOOGL   95.73 (-1.29%)
AMZN   87.71 (-0.61%)
TSLA   173.23 (-3.66%)
NVDA   158.86 (-0.63%)
NIO   12.38 (-6.50%)
BABA   87.99 (-3.78%)
AMD   70.45 (+0.26%)
T   19.34 (+0.89%)
MU   53.52 (-0.30%)
CGC   3.37 (-6.65%)
F   13.29 (+0.08%)
GE   85.47 (+0.22%)
DIS   91.95 (-0.37%)
AMC   6.64 (-1.63%)
PYPL   72.61 (+0.53%)
PFE   50.38 (+1.35%)
NFLX   305.56 (+0.00%)
NASDAQ:PRQR

ProQR Therapeutics - PRQR Stock Forecast, Price & News

$1.44
+0.09 (+6.67%)
(As of 12/7/2022 11:11 AM ET)
Add
Compare
Today's Range
$1.30
$1.47
50-Day Range
$0.74
$1.41
52-Week Range
$0.53
$8.60
Volume
5,771 shs
Average Volume
1.18 million shs
Market Capitalization
$102.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

ProQR Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
119.0% Upside
$3.00 Price Target
Short Interest
Healthy
1.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.96) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

586th out of 1,023 stocks

Pharmaceutical Preparations Industry

280th out of 501 stocks

PRQR stock logo

About ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Stock News Headlines

ProQR Therapeutics NV
Expert Ratings for ProQR Therapeutics
See More Headlines
Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Company Calendar

Last Earnings
11/04/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRQR
Fax
N/A
Employees
1,504
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+108.3%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-72,900,000.00
Net Margins
-2,075.42%
Pretax Margin
-2,080.56%

Debt

Sales & Book Value

Annual Sales
$1.60 million
Book Value
$1.88 per share

Miscellaneous

Free Float
N/A
Market Cap
$102.66 million
Optionable
Optionable
Beta
1.00

Key Executives

  • Dr. Domenico Valerio Ph.D. (Age 66)
    Founder & Independent Chairman of Supervisory Board
    Comp: $69.72k
  • Mr. Daniel Anton de Boer (Age 39)
    Founder, CEO & Member of Management Board
    Comp: $740.03k
  • Ms. Theresa Marie Heggie (Age 62)
    Chief Operating Officer
    Comp: $28.88k
  • Dr. Gerard Platenburg (Age 58)
    Co-Founder & Chief Scientific Officer
  • Ms. Smital Shah M.B.A. (Age 46)
    Chief Bus. & Financial Officer
  • Mr. Rene K. Beukema (Age 58)
    Chief Corp. Devel. Officer, Gen. Counsel & Member of Management Board
  • Ms. Sarah Cue Kiely
    VP of Investor Relations & Corp. Communications
  • Ms. Sheila Sponselee
    VP of HR
  • Mr. Bart Klein
    Sr. VP of Intellectual Property
  • Mr. Aniz Girach M.D. (Age 55)
    Chief Medical Officer













PRQR Stock - Frequently Asked Questions

Should I buy or sell ProQR Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRQR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRQR, but not buy additional shares or sell existing shares.
View PRQR analyst ratings
or view top-rated stocks.

What is ProQR Therapeutics' stock price forecast for 2023?

7 analysts have issued 12-month target prices for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $2.00 to $5.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 122.2% from the stock's current price.
View analysts price targets for PRQR
or view top-rated stocks among Wall Street analysts.

How have PRQR shares performed in 2022?

ProQR Therapeutics' stock was trading at $8.01 on January 1st, 2022. Since then, PRQR shares have decreased by 83.1% and is now trading at $1.35.
View the best growth stocks for 2022 here
.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a decrease in short interest in November. As of November 15th, there was short interest totaling 685,700 shares, a decrease of 34.7% from the October 31st total of 1,050,000 shares. Based on an average trading volume of 670,900 shares, the days-to-cover ratio is presently 1.0 days. Currently, 1.2% of the company's shares are sold short.
View ProQR Therapeutics' Short Interest
.

When is ProQR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PRQR earnings forecast
.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) posted its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.01. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $0.80 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 76.32% and a negative net margin of 2,075.42%.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.83%), BlackRock Inc. (0.70%), Two Sigma Advisers LP (0.24%), Marshall Wace LLP (0.10%), Raymond James & Associates (0.07%) and Simplex Trading LLC (0.00%).

How do I buy shares of ProQR Therapeutics?

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $1.35.

How much money does ProQR Therapeutics make?

ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $96.24 million and generates $1.60 million in revenue each year. The biopharmaceutical company earns $-72,900,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

The company employs 1,504 workers across the globe.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com.

This page (NASDAQ:PRQR) was last updated on 12/7/2022 by MarketBeat.com Staff